Telomir Pharmaceuticals, Inc. TELO
Set alert
0.94 USD -0.03 -3.01%
At close · Oct 30
0.92 -0.02 -1.76%
After hours · Oct 30, 4:00 PM ET
0.7905 Day range 0.9899
0.919 52-week range 1.56
- YTD
- -29.68%
- 1 year
- -37.65%
- Open
- 0.96
- Prev close
- 0.9642
- Mkt cap
- 68.90M
- Vol
- 96.70K
- Avg vol
- 84.05K
- EPS
- -1.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7905
- High
- 0.9899
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 5.77
- Inst. own
- 6.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 4.61
- 200-d avg
- 5.36
- 1y target
- 12.15
6M chart
Signals (38)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 27, 2026 | 3 months ago |
| RSI: Oversold | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 9, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| MACD: Sell Signal | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 138.65M
- Enterprise value
- 152.64M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 310.67
- EPS (TTM)
- -0.77
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 213.65K
- Total cash
- 834.64K
- Total debt
- 93.43K
- Return on equity
- -1752.69%
- Shares outstanding
- 29.75M
- Short % of float
- 3.89%
- 50-day average
- 4.61
- 200-day average
- 5.36
Analyst view
Consensus: none
Price target (mean) 12.15
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.05.
Financials — quick view
TELO Revenue — quarterly 0
TELO Net income — quarterly -1.72M
TELO EPS — quarterly -0.79
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.20 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.05 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.23 | — | — |
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- telomirpharma.com
News
- TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
- Telomir Pharmaceuticals Announces ~$5.6M Investment In PIPE Financing Through Common Stock Issuance
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4
- Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma Models
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on TELO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAY SHORE TRUST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 12, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.89% | 1,151,527 | 5.37M | Sep 29, 2024 |
| Blackrock Inc. | 1.24% | 366,878 | 1.71M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 238,737 | 1.11M | Sep 29, 2024 |
| Suncoast Equity Management | 0.17% | 51,194 | 238.56K | Sep 29, 2024 |
| Bank Of New York Mellon Corporation | 0.17% | 51,364 | 239.36K | Sep 29, 2024 |
| Northern Trust Corporation | 0.16% | 48,680 | 226.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.82% | 834,700 | 3.89M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 261,970 | 1.22M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.32% | 93,887 | 437.51K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.17% | 49,772 | 231.94K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 30,433 | 141.82K | Oct 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.10% | 28,721 | 133.84K | Oct 30, 2024 |